JP2019137675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019137675A5 JP2019137675A5 JP2019019212A JP2019019212A JP2019137675A5 JP 2019137675 A5 JP2019137675 A5 JP 2019137675A5 JP 2019019212 A JP2019019212 A JP 2019019212A JP 2019019212 A JP2019019212 A JP 2019019212A JP 2019137675 A5 JP2019137675 A5 JP 2019137675A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- conjugate according
- seq
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 68
- 102000007238 Transferrin Receptors Human genes 0.000 claims 16
- 108010033576 Transferrin Receptors Proteins 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 210000003205 muscle Anatomy 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 5
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims 4
- 208000033868 Lysosomal disease Diseases 0.000 claims 4
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 208000024720 Fabry Disease Diseases 0.000 claims 3
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 claims 3
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 201000004502 glycogen storage disease II Diseases 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000004220 muscle function Effects 0.000 claims 3
- 230000005996 muscular dysfunction Effects 0.000 claims 3
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 101000718525 Homo sapiens Alpha-galactosidase A Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 1
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 1
- 102000043404 human GLA Human genes 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023150649A JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018018652 | 2018-02-05 | ||
| JP2018018652 | 2018-02-05 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150649A Division JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019137675A JP2019137675A (ja) | 2019-08-22 |
| JP2019137675A5 true JP2019137675A5 (enExample) | 2022-01-18 |
Family
ID=67479985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019212A Pending JP2019137675A (ja) | 2018-02-05 | 2019-02-05 | 薬剤を筋肉に送達するための方法 |
| JP2023150649A Active JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023150649A Active JP7591340B2 (ja) | 2018-02-05 | 2023-09-19 | 薬剤を筋肉に送達するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210038739A1 (enExample) |
| EP (1) | EP3750921A4 (enExample) |
| JP (2) | JP2019137675A (enExample) |
| KR (1) | KR20200116952A (enExample) |
| CN (1) | CN111683972A (enExample) |
| AU (1) | AU2019215782A1 (enExample) |
| BR (1) | BR112020013305A2 (enExample) |
| CA (1) | CA3090373A1 (enExample) |
| EA (1) | EA202091816A1 (enExample) |
| IL (1) | IL276327B2 (enExample) |
| MX (1) | MX2020008041A (enExample) |
| SG (1) | SG11202006433PA (enExample) |
| WO (1) | WO2019151539A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7858532B2 (ja) * | 2020-01-10 | 2026-05-14 | ダイン セラピューティクス，インコーポレーテッド | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
| IL295022A (en) * | 2020-01-31 | 2022-09-01 | Dyne Therapeutics Inc | Antibody against transferrin receptor and uses thereof |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| IL295797A (en) | 2020-02-22 | 2022-10-01 | Japan Chem Res | Human transfer receptor binding peptide |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| JPWO2023022234A1 (enExample) | 2021-08-19 | 2023-02-23 | ||
| US20240366775A1 (en) | 2021-08-24 | 2024-11-07 | Peptidream Inc. | Human transferrin receptor binding antibody-peptide conjugate |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| IL314482A (en) * | 2022-02-02 | 2024-09-01 | Regeneron Pharma | Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| US20260069705A1 (en) * | 2022-06-09 | 2026-03-12 | The Children's Medical Center Corporation | Methods and compositions for enhanced antigen presentation in the tumor microenvironment |
| TW202434613A (zh) | 2023-02-17 | 2024-09-01 | 日商肽夢想股份有限公司 | 人類運鐵蛋白受體結合肽 |
| KR20260021596A (ko) | 2023-04-05 | 2026-02-13 | 아이오니스 파마수티컬즈, 인코포레이티드 | Pln 발현을 감소시키는 화합물 및 방법 |
| IL326018A (en) * | 2023-07-28 | 2026-03-01 | Regeneron Pharma | Introduction of anti-TFR:GAA and anti-CD63:GAA for the treatment of Pompe disease |
| WO2025256433A1 (zh) * | 2024-06-14 | 2025-12-18 | 四川大学华西医院 | 一种转铁蛋白受体1靶向性糖苷水解酶复合体的制备方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2174532A1 (en) | 1993-10-19 | 1995-04-27 | Carlos F. Barbas | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
| AUPN523995A0 (en) | 1995-09-05 | 1995-09-28 | Crc For Biopharmaceutical Research Pty Ltd | Method for producing phage display vectors |
| JP5137814B2 (ja) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート |
| JP5913122B2 (ja) | 2010-11-08 | 2016-04-27 | Ｊｃｒファーマ株式会社 | 新規発現ベクター |
| JP5957085B2 (ja) * | 2012-02-07 | 2016-07-27 | Ｊｃｒファーマ株式会社 | 改善されたバイオアベイラビリティーのためにａｔｆと融合させた薬剤 |
| JP2016514096A (ja) * | 2013-02-20 | 2016-05-19 | バレリオン セラピューティクス， エルエルシー | ポンぺ病の処置のための方法および組成物 |
| SG11201509566RA (en) * | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| MY207684A (en) * | 2015-12-08 | 2025-03-12 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| CN109641971B (zh) * | 2016-08-25 | 2023-04-04 | Jcr制药股份有限公司 | 抗体融合蛋白的制造方法 |
-
2019
- 2019-02-05 CN CN201980011522.2A patent/CN111683972A/zh active Pending
- 2019-02-05 MX MX2020008041A patent/MX2020008041A/es unknown
- 2019-02-05 KR KR1020207024561A patent/KR20200116952A/ko not_active Ceased
- 2019-02-05 JP JP2019019212A patent/JP2019137675A/ja active Pending
- 2019-02-05 SG SG11202006433PA patent/SG11202006433PA/en unknown
- 2019-02-05 CA CA3090373A patent/CA3090373A1/en active Pending
- 2019-02-05 EA EA202091816A patent/EA202091816A1/ru unknown
- 2019-02-05 EP EP19747769.8A patent/EP3750921A4/en active Pending
- 2019-02-05 WO PCT/JP2019/004123 patent/WO2019151539A1/ja not_active Ceased
- 2019-02-05 IL IL276327A patent/IL276327B2/en unknown
- 2019-02-05 AU AU2019215782A patent/AU2019215782A1/en not_active Abandoned
- 2019-02-05 US US16/963,956 patent/US20210038739A1/en not_active Abandoned
- 2019-02-05 BR BR112020013305-1A patent/BR112020013305A2/pt unknown
-
2023
- 2023-09-19 JP JP2023150649A patent/JP7591340B2/ja active Active
-
2024
- 2024-03-08 US US18/599,591 patent/US20240245797A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7411316B2 (ja) | 三重特異性結合タンパク質と使用方法 | |
| TWI614264B (zh) | 含胜肽核的多臂接合物及其應用 | |
| TWI617319B (zh) | 用以治療病理性血栓的融合蛋白 | |
| TWI591075B (zh) | 含胜肽核的多臂接合物 | |
| JPH05502039A (ja) | 多価抗原結合性蛋白質 | |
| US20230118983A1 (en) | Tetravalent FZD and WNT Co-receptor Binding Molecules and Uses Thereof | |
| JP2022081634A (ja) | プロテアーゼで切断可能なリンカーを有するペプチド構築体 | |
| JP6953467B2 (ja) | 組換えタンパク質及びそれらの治療的用途 | |
| JP2013507115A (ja) | 「終末糖化産物受容体」への結合のためのポリペプチド、さらにはそれを含む組成物及び方法 | |
| JP2008521426A5 (enExample) | ||
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 | |
| KR102444797B1 (ko) | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 | |
| US20240270797A1 (en) | Coronavirus neutralizing compositions and associated methods | |
| CN120590542A (zh) | 基于clec9a的嵌合蛋白复合物 | |
| WO2019192493A1 (zh) | 抗人lag-3单克隆抗体及其应用 | |
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| JP2022513626A5 (enExample) | ||
| JP2024527571A (ja) | インターロイキン－１アルファキメラタンパク質 | |
| TW201809013A (zh) | 用於藥物遞送之抗體融合蛋白 | |
| TH2001004295A (th) | องค์ประกอบทางเภสัชกรรมสำหรับปรับปรุงการทำหน้าที่ของกล้ามเนื้อให้ดีขึ้น | |
| NZ794344B2 (en) | TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN | |
| NZ794344A (en) | Tgfβr2 extracellular domain truncated molecule, fusion protein of tgfβr2 extracellular domain truncated molecule and anti-egfr antibody, and anti-tumor use of fusion protein | |
| WO2024140919A1 (zh) | 抗crtam/抗pd-l1抗体及其应用 | |
| CA3238965A1 (en) | B7-h4 antibodies and anti-b7-h4 antibody/il-15 fusion proteins |